FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2418508482> ?p ?o ?g. }

• W2418508482 endingPage "6" @default.
• W2418508482 startingPage "441" @default.
• W2418508482 abstract "To investigate the effect of the proteasome inhibitor MG-132 on skeletal muscle atrophy in a rat model of chronic obstructive pulmonary disease (COPD) and its potential mechanisms.The COPD rat model was established by instillation of LPS and exposure to the cigarette smoke. Then the COPD rats were randomly divided into 3 groups (each group n = 12): COPD model control group, MG-132 high dose group (MG-132 0.1 mg·kg(-1)·d(-1)) and low dose group (MG-132 0.05 mg·kg(-1)·d(-1)), and normal control group. After 1 week and 4 week, 6 rats of each group were sacrificed, and then the following parameters were determined: the weight of the diaphragm muscle, the concentration of TNF-α in the serum and diaphragm via enzyme-linked immunosorbent assay (ELISA). Muscle atrophy F-box protein (MAFbx), NF-κBp65, and IκB-α mRNA levels were determined by RT-PCR. The protein levels of MAFbx, NF-κBp65 and IκB-α in diaphragm were measured by Western blot. The single factor analysis of variance was used for statistical analysis among the groups, while t test was used for comparison between 2 groups, and Pearson linear correlation analysis was also performed.The weight of diaphragm muscle from 1 week and 4 week normal control group [(0.99 ± 0.06) mg and (1.20 ± 0.04) mg] were reduced as compared to those of COPD model control group [(0.83 ± 0.09) mg and (1.01 ± 0.06) mg], high dose group [(0.85 ± 0.02) mg and (1.11 ± 0.06) mg], and low dose group [(0.83 ± 0.03) mg and (1.04 ± 0.02) mg]. The reduction of diaphragm muscle weight in the high dose group and the low dose group was significantly less than that in the COPD model control group, with a more marked difference as compared with the 4 week high dose group. The TNF-α levels in diaphragm from 4 week high dose group [(106 ± 8) ng/L] and low dose group [(122 ± 7) ng/L] were decreased as compared to that of the COPD model control group [(143 ± 24) ng/L]. The levels of NF-κBp65 and MAFbx mRNA from the 4 week high dose group (2.17 ± 0.42) and low dose group (1.74 ± 0.14) and the protein expression (1.13 ± 0.04 and 1.27 ± 0.05) were also decreased as compared to those of the COPD model control group (mRNA 2.81 ± 0.31 and 4.87 ± 0.34, protein expression 1.32 ± 0.04 and 1.44 ± 0.07). The levels of IκB-α mRNA and protein expression (0.96 ± 0.08 and 0.83 ± 0.06) were higher than those of the COPD model control group (0.25 ± 0.02 and 0.58 ± 0.06), (t = 1.57-24.9, P < 0.05). The levels of the TNF-α levels in serum and diaphragm were correlated positively with the levels of MAFbx and NF-κBp65 mRNA and protein expression (r = 0.672-0.875, P < 0.01), but negatively with the levels of IκB-α mRNA and protein expression (r = -0.656--0.927, P < 0.01).The proteasome inhibitor MG-132 significantly inhibited IκB-α degradation thus preventing NF-κB activation. This effect resulted in preventing skeletal muscle atrophy in the COPD rats." @default.
• W2418508482 created "2016-06-24" @default.
• W2418508482 creator A5006930754 @default.
• W2418508482 creator A5022783857 @default.
• W2418508482 creator A5026769100 @default.
• W2418508482 creator A5066911325 @default.
• W2418508482 creator A5079962090 @default.
• W2418508482 date "2013-06-01" @default.
• W2418508482 modified "2023-09-23" @default.
• W2418508482 title "[The proteasome inhibitor MG132 attenuates skeletal muscle atrophy in a rat model of chronic obstructive pulmonary disease]." @default.
• W2418508482 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24103208" @default.
• W2418508482 hasPublicationYear "2013" @default.
• W2418508482 type Work @default.
• W2418508482 sameAs 2418508482 @default.
• W2418508482 citedByCount "1" @default.
• W2418508482 countsByYear W24185084822018 @default.
• W2418508482 crossrefType "journal-article" @default.
• W2418508482 hasAuthorship W2418508482A5006930754 @default.
• W2418508482 hasAuthorship W2418508482A5022783857 @default.
• W2418508482 hasAuthorship W2418508482A5026769100 @default.
• W2418508482 hasAuthorship W2418508482A5066911325 @default.
• W2418508482 hasAuthorship W2418508482A5079962090 @default.
• W2418508482 hasConcept C104317684 @default.
• W2418508482 hasConcept C121332964 @default.
• W2418508482 hasConcept C126322002 @default.
• W2418508482 hasConcept C134018914 @default.
• W2418508482 hasConcept C157138929 @default.
• W2418508482 hasConcept C164292776 @default.
• W2418508482 hasConcept C185592680 @default.
• W2418508482 hasConcept C24890656 @default.
• W2418508482 hasConcept C2776263037 @default.
• W2418508482 hasConcept C2776364478 @default.
• W2418508482 hasConcept C2776415932 @default.
• W2418508482 hasConcept C2776780178 @default.
• W2418508482 hasConcept C2778367456 @default.
• W2418508482 hasConcept C2778506107 @default.
• W2418508482 hasConcept C2779959927 @default.
• W2418508482 hasConcept C2781172350 @default.
• W2418508482 hasConcept C3019114686 @default.
• W2418508482 hasConcept C55493867 @default.
• W2418508482 hasConcept C71924100 @default.
• W2418508482 hasConcept C99476002 @default.
• W2418508482 hasConceptScore W2418508482C104317684 @default.
• W2418508482 hasConceptScore W2418508482C121332964 @default.
• W2418508482 hasConceptScore W2418508482C126322002 @default.
• W2418508482 hasConceptScore W2418508482C134018914 @default.
• W2418508482 hasConceptScore W2418508482C157138929 @default.
• W2418508482 hasConceptScore W2418508482C164292776 @default.
• W2418508482 hasConceptScore W2418508482C185592680 @default.
• W2418508482 hasConceptScore W2418508482C24890656 @default.
• W2418508482 hasConceptScore W2418508482C2776263037 @default.
• W2418508482 hasConceptScore W2418508482C2776364478 @default.
• W2418508482 hasConceptScore W2418508482C2776415932 @default.
• W2418508482 hasConceptScore W2418508482C2776780178 @default.
• W2418508482 hasConceptScore W2418508482C2778367456 @default.
• W2418508482 hasConceptScore W2418508482C2778506107 @default.
• W2418508482 hasConceptScore W2418508482C2779959927 @default.
• W2418508482 hasConceptScore W2418508482C2781172350 @default.
• W2418508482 hasConceptScore W2418508482C3019114686 @default.
• W2418508482 hasConceptScore W2418508482C55493867 @default.
• W2418508482 hasConceptScore W2418508482C71924100 @default.
• W2418508482 hasConceptScore W2418508482C99476002 @default.
• W2418508482 hasIssue "6" @default.
• W2418508482 hasLocation W24185084821 @default.
• W2418508482 hasOpenAccess W2418508482 @default.
• W2418508482 hasPrimaryLocation W24185084821 @default.
• W2418508482 hasRelatedWork W1989047233 @default.
• W2418508482 hasRelatedWork W2032675594 @default.
• W2418508482 hasRelatedWork W2094585730 @default.
• W2418508482 hasRelatedWork W2127318580 @default.
• W2418508482 hasRelatedWork W2327327314 @default.
• W2418508482 hasRelatedWork W2339029146 @default.
• W2418508482 hasRelatedWork W2418508482 @default.
• W2418508482 hasRelatedWork W3030016882 @default.
• W2418508482 hasRelatedWork W3120093330 @default.
• W2418508482 hasRelatedWork W4289262306 @default.
• W2418508482 hasVolume "36" @default.
• W2418508482 isParatext "false" @default.
• W2418508482 isRetracted "false" @default.
• W2418508482 magId "2418508482" @default.
• W2418508482 workType "article" @default.